leftPREV NEXTright
[Article] NA Vaccine Institute selected as a global vaccine technology leader for flu and peptide tuberculosis vaccines
Writer 최고관리자
NA Vaccine Institute, a vaccine development company, announced on the 26th that the influenza vaccine and peptide tuberculosis vaccine using its self-developed mucosal immunity enhancer platform were selected for the first new project hosted by the Global Vaccine Leading Technology Center.

Global Vaccine Leading Technology Center supports the entire vaccine research and development (R&D) cycle of companies in order to quickly respond to the infectious disease pandemic and advance into the global market through the development of high value-added vaccine technology.

Through this project, NA Vaccine Institute will receive support for three years for the verification and development of universal and multivalent influenza vaccines and peptide-based tuberculosis vaccines using a next-generation mucosal adjuvant platform. The company plans to secure efficacy and safety data for the two vaccine candidates and conduct phase 1 clinical trials within three years.

The universal and multivalent influenza vaccines being developed by the NA Vaccine Institute are made into an inhalable form by mixing 'Nexavant', a new immune enhancer for mucous membranes discovered by the company, with an existing seasonal influenza vaccine on the market. Compared to existing vaccines, it can block a wider range of flu viruses, making it possible to respond quickly to future influenza pandemics. In addition, the tuberculosis vaccine is a vaccine formulated with NA Vaccine Institute's peptide and Nexavant, which can increase the efficacy of BCG, which is currently the only tuberculosis vaccine. The peptide tuberculosis vaccine is evaluated as not only economical and effective, but also can be stored at room temperature.

An official from the NA Vaccine Institute said, “Through this support, we will be able to improve and replace the existing vaccine system in the mid- to long-term,” and added, “We will continue to work to develop various vaccines and immunotherapies.”
LIST